Literature DB >> 15766292

Tachyphylaxis in unipolar major depressive disorder.

David A Solomon1, Andrew C Leon, Timothy I Mueller, William Coryell, Jedediah J Teres, Michael A Posternak, Lewis L Judd, Jean Endicott, Martin B Keller.   

Abstract

BACKGROUND: Major depressive disorder is usually a recurring illness, and maintenance treatment is used to forestall or prevent recurrent episodes of depression. This study describes recurrence of major depression despite maintenance pharmacotherapy, termed tachyphylaxis.
METHOD: The study sample consisted of 103 subjects who participated in the NIMH Collaborative Depression Study, a multicenter longitudinal observational study of the mood disorders. Subjects diagnosed with unipolar major depressive disorder according to Research Diagnostic Criteria were enrolled from 1978-1981 and prospectively followed for up to 20 years. As an observational study, treatment was recorded but not controlled by anyone connected with the study. Subjects were selected for the present study if at some point during follow-up they received antidepressant medication for treatment of an episode of major depressive disorder, recovered from this episode, and subsequently received maintenance pharmacotherapy. Some subjects were successfully treated for multiple episodes of major depressive disorder and then received maintenance medication after each of these episodes, resulting in multiple maintenance treatment intervals. Data were collected using the Longitudinal Interval Follow-Up Evaluation, and mixed-effects logistic regression was used to test the association of sociodemographic and clinical variables with tachyphylaxis.
RESULTS: For the 103 subjects, there were 171 maintenance treatment intervals in which a subject received maintenance pharmacotherapy after having recovered from an episode of major depressive disorder. The median duration of maintenance treatment was 20 weeks. Tachyphylaxis occurred during 43 (25%) of these 171 maintenance treatment intervals. The subtype of melancholic (endogenous) major depressive disorder significantly elevated the risk of tachyphylaxis during the subsequent maintenance treatment interval.
CONCLUSIONS: Despite the use of maintenance pharmacotherapy, major depression recurs in a considerable number of patients. Improved prophylaxis for these patients requires other treatment strategies based upon a greater understanding of recurrence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766292     DOI: 10.4088/jcp.v66n0302

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

1.  Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.

Authors:  Florian Seemüller; Sebastian Meier; Michael Obermeier; Richard Musil; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Michael Riedel; Peter Falkai; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03-04       Impact factor: 5.270

2.  Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).

Authors:  Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink
Journal:  Arch Gen Psychiatry       Date:  2006-12

3.  Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression.

Authors:  Zindel V Segal; Peter Bieling; Trevor Young; Glenda MacQueen; Robert Cooke; Lawrence Martin; Richard Bloch; Robert D Levitan
Journal:  Arch Gen Psychiatry       Date:  2010-12

4.  Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Robert J DeRubeis
Journal:  Bipolar Disord       Date:  2016-11-02       Impact factor: 6.744

Review 5.  Identification and treatment of antidepressant tachyphylaxis.

Authors:  Steven D Targum
Journal:  Innov Clin Neurosci       Date:  2014-03

6.  Does major depressive disorder change with age?

Authors:  W Coryell; D Solomon; A Leon; J G Fiedorowicz; P Schettler; L Judd; M Keller
Journal:  Psychol Med       Date:  2009-03-19       Impact factor: 7.723

7.  Clinical implications of genetic variation in the serotonin transporter promoter region: a review.

Authors:  Nicole S Luddington; Anitha Mandadapu; Margaret Husk; Rif S El-Mallakh
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.

Authors:  Anthony J Rothschild; Boadie W Dunlop; David L Dunner; Edward S Friedman; Alan Gelenberg; Peter Holland; James H Kocsis; Susan G Kornstein; Richard Shelton; Madhukar H Trivedi; John M Zajecka; Corey Goldstein; Michael E Thase; Ron Pedersen; Martin B Keller
Journal:  Psychopharmacol Bull       Date:  2009

9.  Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries.

Authors:  Cuneyt Tegin; Gulay Tegin; Rif S El-Mallakh
Journal:  Psychopharmacol Bull       Date:  2018-01-15

10.  Preventing recurrent depression: long-term treatment for major depressive disorder.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.